ERAS-007, a potential best-in-class ERK1/2 inhibitor, will be evaluated initially in combinations that could address over half of patients with colorectal cancer SAN DIEGO, Sept. 22, 2021 (GLOBE ...
First patient dosed in IDE397 combination with pemetrexed, representing a novel and potential first-in-class combination in MTAP-deletion tumors First patient dosed in IDE397 combination with taxane ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results